antagonist ͉ enzyme ͉ knockout mice ͉ receptor ͉ selenium tetrachloride T he somnogenic activity of prostaglandin (PG) D 2 was originally discovered serendipitously when we microinjected nanomolar quantities of PGD 2 in the preoptic area of rats (1). Subsequent studies using a continuous-infusion circadian sleep bioassay system revealed that the effect was specific to PGD 2 because other PGs were almost totally inactive (2). Infusion with as little as picomolar quantities per minute was sufficient to induce excess amounts of both non-rapid eye movement (NREM) and rapid eye movement (REM) sleep. Sleep induced by PGD 2 was indistinguishable from physiological sleep as judged by several behavioral and electrophysiological criteria, including power spectral analysis (3). PGD 2 was not pyrogenic, and it actually caused a slight decrease in the body temperature, as is observed to occur during physiological sleep. These results suggested the possibility that PGD 2 might be a sleep hormone (4-7).
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PGD 2 is the most abundant prostanoid in the brains of rats (8) and other mammals, including humans (9); and it is produced in the brain from the substrate PGH 2 , a common intermediate of various prostanoids, by the action of PGD synthase (PGDS; PGH 2 D-isomerase, EC 5.3.99.2). Two distinct types of PGDS were purified from the brain (10) and spleen (11) of rats in our and other laboratories, and their structures were determined by x-ray crystallography (12, 13) . One was the lipocalin-type PGDS (L-PGDS) (10, 14, 15) , mainly expressed in the arachnoid membrane, choroids plexus, and oligodendrocytes in the brain (14, 16) ; and the other was hematopoietic PGDS (H-PGDS) (17, 18) , localized in mast cells (19) and microglia (20, 21) . Inorganic tetravalent selenium compounds were found to be potent, relatively specific, and reversible inhibitors of PGDS when tested in vitro (22) . These inhibitors seemed to interact with the free sulfhydryl group in the active site of PGDS because the inhibition could be reversed by the addition of excess amounts of SH compounds such as glutathione or DTT. In 1991, Matsumura and coworkers (23) administered selenium tetrachloride (SeCl 4 ) into the third ventricle of sleeping rats, and they found that sleep was inhibited almost completely after Ϸ2 h from the start of the infusion. The effect was reversible because when the infusion was interrupted, sleep was restored. Furthermore, the inhibition was reversed by the simultaneous infusion of SH compounds such as DTT and glutathione, as in the case of the in vitro enzyme activity. These results indicated that PGDS plays an essential role in the maintenance of sleep and, therefore, that PGD 2 is involved in sleep under physiological conditions in rodents.
Our recent studies with gene knockout (KO) mice for PGDS and prostaglandin D receptors (DP 1 R) specific for PGD 2 showed that mice depleted of these genes did not exhibit NREM sleep rebound after sleep deprivation, suggesting that PGD 2 is crucial for the homeostatic regulation of NREM sleep (24) . However, KO mice for PGDS or DP 1 R did not show any changes in the circadian profile and total time of NREM and REM sleep compared with WT mice under baseline conditions, raising questions about the involvement of PGD 2 in the regulation of physiological sleep.
In this work, we administered SeCl 4 by an i.p. bolus injection during the sleeping period into wild-type (WT) mice as well as into KO mice lacking H-PGDS, L-PGDS, H-and L-PGDS (HL-PGDS), or DP 1 R, and we studied their sleep-wake behavior. The SeCl 4 administration inhibited sleep promptly and effectively in WT and H-PGDS KO mice but not at all in the other three types of KO mice, indicating that SeCl 4 inhibited sleep by blocking the endogenous production of PGD 2 by L-PGDS and not by some nonspecific or general toxic effects of selenium per se. We also examined the effect of a DP 1 R antagonist ONO-4127Na on the sleep of rats, and we found that this antagonist reduced the sleep during infusion into the subarachnoid space under the rostral basal forebrain, in which DP 1 R is dominantly localized (25) . These results indicate again that PGD 2 plays a crucial role in the regulation of physiological sleep.
Results
Blockade of DP1R Decreased NREM and REM Sleep in Rats. We infused the DP 1 R antagonist ONO-4127Na into the subarachnoid space underlying the rostral basal forebrain of rats through a cannula for 6 h from 0900 to 1500 to investigate the changes in the sleep-stage distribution. As shown in Fig. 1A , ONO-4127Na infusion at 200 pmol͞min caused a significant decrease in NREM and REM sleep: ONO-4127Na decreased NREM sleep hourly by 30-40%, and it reduced REM sleep by 60-90% commencing Ϸ2 h after the beginning of ONO-4127Na infusion compared with the baseline. This reduction in sleep time was accompanied by an increase in wakefulness. ONO-4127Na (200 pmol͞min) increased the wakefulness time 2.4-fold starting Ϸ2 h after the beginning of the infusion, and this increase lasted until 1 h after the cessation of infusion. There was no further disruption of the sleep architecture during the subsequent period. Similar time course profiles were observed with a lower concentration of 100 pmol͞min. However, ONO-4127Na infusion at 50 pmol͞min had little effect on the sleep-stage distribution.
We calculated the total time spent in wakefulness and NREM and REM sleep for 7 h, that is, during the ONO-4127Na perfusion for 6 h and 1 h postinfusion (Fig. 1B) . ONO-4127Na given at 100 and 200 pmol͞min reduced NREM sleep by 23% and 28% and REM sleep by 49% and 63%, and it increased the total amount of wakefulness by 1.6-and 1.8-fold, respectively, during that 7-h period. There was essentially no difference between ONO-4127Na (50 pmol͞min) infusion and the baseline day. These results clearly indicate that ONO-4127Na dosedependently reduced NREM and REM sleep and concomitantly increased wakefulness.
Inhibition of Mouse Brain PGDS in Vitro and in Vivo by SeCl4. When we examined the effect of SeCl 4 on the activities of mouse L-PGDS and H-PGDS in vitro, we found that it inhibited both L-PGDS and H-PGDS efficiently in a concentration-dependent manner, giving IC 50 values of 40 and 90 M, respectively ( Fig.  2A ). To investigate whether SeCl 4 inhibits PGDS in vivo, we then determined the PGD 2 content in the brain of WT mice at 2 h after an i.p. injection of SeCl 4 at a dose of 1.25, 2.5, or 5 mg͞kg of body weight. As shown in Fig. 2B , whereas SeCl 4 given at 1.25 mg͞kg had little effect on the PGD 2 content in the brain, at 2.5 and at 5 mg͞kg it reduced the PGD 2 content by 52% and 59%, respectively, without changing the PGE 2 and PGF 2␣ contents, indicating that the SeCl 4 administration selectively inhibited the production of PGD 2 in the brain in vivo without affecting the production of other PGs.
Inhibition of NREM and REM Sleep of WT Mice by SeCl4 Administration.
Next we examined the sleep-wake pattern of WT mice by measuring their electroencephalogram (EEG) and electromyogram (EMG) before and after an i.p. bolus injection of SeCl 4 at doses of 1.25, 2.5, 4, and 5 mg͞kg at 1100 during the sleep period. The typical time courses of the hourly amounts of NREM and REM sleep and wakefulness and their cumulative amounts for 5 h after injection are summarized in Figs. 3 and 4, respectively. In the case of 1.25 mg͞kg SeCl 4 , the sleep-wake pattern was almost identical before and after the injection, similar to the pattern of PGD 2 content in the brain. SeCl 4 at 2.5 mg͞kg slightly reduced both NREM and REM sleep for 2-3 h after the injection (Fig. 3A) . At this dose, the cumulative amounts of NREM and REM sleep for 5 h postinjection significantly decreased by 23% and 44%, respectively, and the amount of wakefulness increased 1.5-fold (Fig. 4) . At doses of 4 and 5 mg͞kg SeCl 4 , both NREM and REM sleep decreased promptly after the injection; and SeCl 4 -injected mice displayed almost complete insomnia within 1 h. The sleep suppression gradually decreased thereafter, lasting Ϸ3 and 5 h after the injection of 4 and 5 mg͞kg SeCl 4 , respectively; and both NREM and REM sleep increased remarkably during the following nighttime (Fig.  3B ). SeCl 4 given at 4 and 5 mg͞kg reduced the 5-h cumulative amount of NREM sleep during the daytime by 31% and 45% and that of REM sleep by 63% and 81%, respectively, and it increased that of wakefulness time by 1.7-and 2.1-fold, respectively (Fig. 4) . It also induced a strong rebound-like reaction during the following nighttime to increase the 6 h-cumulative amount of NREM sleep 2.2-and 2.4-fold, REM sleep 5.5-and 3.9-fold, and to decrease the amount of wakefulness time by 36% and 41%, respectively. These results revealed that SeCl 4 given during the light period dose dependently inhibited NREM and REM sleep of WT mice and increased both during the following dark period.
Effect of SeCl4 on NREM and REM Sleep of KO Mice Lacking H-PGDS,
L-PGDS, HL-PGDS, or DP 1 R. We then administered SeCl 4 at 5 mg͞kg to WT or various KO mice lacking H-PGDS, L-PGDS, HL-PGDS, or DP 1 R, and we compared the effect on the sleep-wake cycle between the WT and these KO mice. In H-PGDS KO mice, SeCl 4 also inhibited both NREM and REM sleep by 80% and almost completely, respectively, and it increased the wake time Ϸ2-fold for 1 h after the injection (Fig. 3C) . The hourly amounts of NREM sleep and wakefulness returned to the vehicle-injected level within 2-3 h after the administration, but the REM sleep suppression was prolonged for 6 h. H-PGDS KO mice showed strong NREM and REM sleep induction and suppression of wakefulness during the following dark period, similar to the WT mice. In the comparison of the cumulative amounts, NREM and REM sleep for 5 h after the injection decreased by 27% and 78%, respectively, and the wakefulness increased by 1.7-fold (Fig. 4) . The cumulative amounts of NREM and REM sleep for 6 h during the following dark period increased 2.4-and 4.1-fold, respectively, and that of wakefulness decreased by 47%. Between the WT and H-PGDS KO mice, there was no statistically significant difference in the responsiveness of NREM and REM sleep and wakefulness to the SeCl 4 administration, suggesting that H-PGDS was most likely not involved in the SeCl 4 -induced insomnia.
In contrast, when L-PGDS KO mice were examined, SeCl 4 did not change the amounts of NREM and REM sleep or the time spent in wakefulness at all during the daytime (Figs. 3D and 4) , clearly indicating that the sleep inhibition immediately after the administration of SeCl 4 depended on L-PGDS. However, interestingly, the SeCl 4 administration to L-PGDS KO mice increased both NREM and REM sleep and decreased wakefulness time during the following nighttime (Fig. 3D) . The 6-h cumulative amounts of the NREM and REM sleep during the dark period increased almost 2-fold, and that of wakefulness time decreased Ϸ25%. Between the WT and L-PGDS KO mice, there was no statistically significant difference in the increase in NREM or REM sleep or in the decrease in wakefulness during the nighttime after the SeCl 4 administration, indicating that L-PGDS was not involved in the delayed sleep induction by SeCl 4 . The delayed sleep induction was considered to be mediated by PGD 2 produced by H-PGDS and recognized by DP 1 R because it was not observed in HL-PGDS double KO mice or in DP 1 R KO mice, as described below.
When SeCl 4 was administered to HL-PGDS double KO mice (Fig. 3E) or to DP 1 R KO mice (Fig. 3F) under the same experimental conditions, neither the inhibition of sleep immediately after administration of SeCl 4 nor the delayed increase in sleep during the night was observed. These results clearly show that SeCl 4 was not toxic to inhibit sleep per se, but it suppressed sleep by inhibiting the endogenous production of PGD 2 , whose information is transferred by DP 1 R to induce sleep. These results also suggest that sleep in WT mice is controlled by PGD 2 produced by L-PGDS, rather than H-PGDS, and it is recognized by DP 1 R under physiological conditions.
Discussion
The present study showed that SeCl 4 inhibited sleep almost immediately after the administration of it to WT mice and H-PGDS KO mice, but it failed to do so in L-PGDS KO, HL-PGDS double KO, and DP 1 R KO mice, indicating that L-PGDS is the enzyme responsible for the synthesis of PGD 2 involved in sleep regulation and that the selenium compound inhibited sleep through the L-PGDS͞PGD 2 ͞DP 1 R system (7).
It is known that selenium compounds are toxic to several species of mammals (26), despite being an essential trace element and the fact that selenocysteine is present in the active site of glutathione peroxidase (27) and a component of other proteins such as selenoprotein P (26) . If the observed reduction in sleep had been caused by some toxic effect of selenium, similar changes in the sleep-wake profiles would have been expected in WT, L-, H-PGDS, HL-PGDS double and DP 1 R KO mice, let alone the overt behavioral changes that are common consequences of toxicity. Nevertheless, SeCl 4 merely caused a significant reduction in the amount of sleep of the WT and H-PGDS KO mice, and it had no effect on the other KO mice, thereby eliminating the possibility of some toxicological effect of SeCl 4 . In addition, when SeCl 4 was infused into the third ventricle of rats during the light period, sleep was inhibited both time-and dose-dependently, and the inhibition was reversed when the infusion was interrupted. Likewise, the effect was reversed by the simultaneous infusion of sulfhydryl compounds such as DTT and reduced glutathione. Furthermore, throughout the sleepinhibition period caused by selenium administration, all rats displayed normal behaviors similar to those observed during the natural wake phase (23) . Recently, Lee et al. (28) reported that intracerebroventricular infusion of SeCl 4 increased the arousallike behavior in unanesthetized fetal sheep and that the effect could be abolished by subsequent administration of PGD 2 . These findings further indicate that SeCl 4 -induced sleep inhibition may indeed be attributed to L-PGDS inhibition and not to selenium intoxication.
It is noteworthy that the amount of sleep in L-PGDS KO mice increased during the dark period when SeCl 4 was given during the light period, whereas HL-PGDS double KO and DP 1 R KO mice were not affected in this way, suggesting that H-PGDS may be involved in the increase in sleep during the dark period. The physiological meaning of this ''pseudo-rebound'' phenomenon is unknown at present, and further experiments are required to clarify this issue.
Here we showed L-PGDS and DP 1 R to be important in sleep induced by PGD 2 . When the DP 1 R antagonist ONO-4127Na was infused into the subarachnoid space in the rostral basal forebrain of a sleeping rat, where DP 1 R are densely localized, sleep was inhibited dose-and time-dependently and reversibly during the period of infusion. However, L-PGDS, DP 1 R, and HL-PGDS double KO mice displayed NREM and REM sleep circadian profiles identical to those of WT mice under baseline conditions. Similar phenomena were also found in mice with knockout of other sleep-wake-related genes, such as those for the histamine H 1 receptor (29, 30) , orexin (31) , and the adenosine A 1 and A 2A receptors (32, 33) . Considering that sleep is essential for life, it is not surprising that the sleep-regulatory system would be composed of a complicated network of systems in which the deficiency of one system may be effectively compensated by the other systems during embryonic development (24) . However, when mice were subjected to sleep deprivation, L-PGDS KO mice exhibited little NREM sleep rebound, without any increase in PGD 2 content in the brain, whereas WT mice displayed a pronounced sleep rebound especially in the NREM sleep, with concomitant increase in PGD 2 content in the brain after sleep deprivation (24) , indicating that endogenous PGD 2 is involved in the homeostatic regulation of NREM sleep.
In conclusion, SeCl 4 inhibited sleep in WT mice, concomitant with a reduction in the PGD 2 content in the brain. The sleep inhibition was also observed in H-PGDS KO mice, but not in L-PGDS, HL-PGDS double or DP 1 R KO mice. We conclude that PGD 2 is not only involved in the homeostatic regulation of sleep but also essential for the initiation and maintenance of normal circadian sleep under physiological conditions.
Materials and Methods
Animals. L-PGDS KO and H-PGDS KO mice were generated at Osaka Bioscience Institute (Osaka, Japan) and DP 1 R KO mice, at Kyoto University (Kyoto, Japan), as reported in detail by Eguchi et al. (34) , Trivedi et al. (35) , and Matsuoka et al. (36) , respectively. All of these KO mice were back-crossed to the C57BL͞6 strain for Ͼ20 generations. Heterozygous mice for either the H-or L-PGDS gene mutation were cross-bred to generate double heterozygous mice. These double heterozygous mice were then cross-bred to produce the WT, H-PGDS KO, L-PGDS KO, and HL-PGDS double KO mice used in this work. Male WT, L-, H-, and HL-PGDS double and DP 1 R KO mice of the inbred C57BL͞6 strain, weighing 25-28 g (11-13 weeks), were maintained at Oriental Bioservice (Kyoto, Japan).
H-and L-PGDS deficiencies were confirmed by Southern blotting and PCR analysis of DNA prepared from clipped tails and by Western blotting with antibodies against H-and L-PGDS proteins, as described in refs. 34 and 35. Physical attributes of the HL-PGDS double KO mice were basically the same as those of the WT, H-PGDS KO, and L-PGDS KO mice as judged by the growth curves of body weight covering up to 40 weeks of age and visual observation of their behaviors.
Male Sprague-Dawley rats weighing 250-320 g (8-10 weeks) were purchased from Shizuoka Laboratory Animal Center (Shizuoka, Japan). Both mice and rats were housed in an insulated sound-proofed recording room maintained at an ambient temperature of 24 Ϯ 0.5°C with a relative humidity of 60 Ϯ 2% on an automatically controlled 12-h light͞dark cycle (light on at 0800), and they had free access to food and water. The experimental protocols were approved by the Animal Care Committee of Osaka Bioscience Institute, and every effort was made to minimize the number of animals used as well as any pain and discomfort.
Chemicals. ONO-4127Na was produced and provided by Ono Pharmaceutical Co., Ltd. (Osaka, Japan). This compound exhibited a high specific binding affinity for the DP 1 R (K i ϭ 0.0025 M) compared with other prostanoid receptors ( Table 1 , which is published as supporting information on the PNAS web site) and antagonism toward DP 1 R (pA 2 ϭ 9.73; see Table 2 , which is published as supporting information on the PNAS web site), based on the results of competitive binding assays and agoniststimulated cAMP accumulation assays with mouse DP 1 Rexpressing stable transformants of Chinese hamster ovary cells (37) (38) (39) (40) . ONO-4127Na is almost insoluble in physiological saline or artificial cerebrospinal fluid, but it is soluble in 5% sucrose with a solubility limit at 5 ϫ 10 Ϫ4 M. Therefore, the maximum dosage of the drug allowed for infusion into the rat brain was 200 pmol at a rate of 0.4 l͞min. SeCl 4 (Wako Pure Chemicals, Osaka, Japan) was dissolved in sterile saline. Aliquots were prepared and stored frozen at Ϫ20°C. For each experiment, the aliquots were thawed, and the pH was adjusted to 7.2 by the addition of 0.2 M NaOH immediately before use. Polygraphic Recordings in Rats and Mice. Under pentobarbital anesthesia (50 mg͞kg, i.p.), rats underwent surgery for implantation of electrodes for EEG and EMG recordings and placement of a stainless-steel cannula (0.35-mm diameter) for infusion of ONO-4127Na as described earlier (43) . The cannulae were inserted in a midline position, 1.1 mm anterior to bregma, to a depth of 7.8-8.0 mm below the dura. The cannulae thus inserted were directed at the subarachnoid space under the rostral basal forebrain, the area defined as a PGD 2 -sensitive sleep-promoting zone (43) . Postoperatively, the rats were housed individually for 8-10 days.
Under pentobarbital anesthesia (50 mg͞kg, i.p.), mice were chronically implanted with EEG and EMG electrodes for polysomnographic recordings. The implant consisted of two stainless-steel screws (1-mm diameter) serving as EEG electrodes, inserted, according to the atlas of Franklin and Paxinos (44) , through the skull into the cortex (anteroposterior, ϩ1.0 mm and ϩleft-right, Ϫ1.5 mm from bregma or lambda); and two insulated, stainless-steel, Teflon-coated wires, serving as EMG electrodes, which were bilaterally placed into both trapezius muscles., All electrodes were attached to a microconnector and fixed to the skull with dental cement (29, 33) . Postoperatively, the animals were housed individually for 8-10 days.
The recordings of EEG and EMG were carried out by means of a slip ring, designed so that behavioral movement of the animal would not be restricted. After a 10-day recovery period, the mice or rats were housed individually in transparent barrels and habituated to the recording cable for 3-4 days before starting the polygraphic recordings. The rats were infused continuously with artificial cerebrospinal fluid into the brain at a speed of 0.4 l͞min. Sleep-wakefulness states were monitored for a period of 48 h, which comprised baseline and experimental days. Baseline recordings were taken in each animal for 24 h, beginning at 0800, which served as the control for the same animal. On the next day, ONO-4127Na (50, 100, or 200 pmol͞ min) was infused into the rat brain between 0900 and 1500 for 6 h. Each mouse was i.p. injected with saline (20 ml͞kg of body weight) at 1100 on the 1st day. The next day, again at 1100, SeCl 4 was injected i.p. at a dose of 1.25, 2.5, 4, or 5 mg͞kg; and EEG͞EMG activity was collected for another 24 h.
Cortical EEG and EMG signals were amplified and filtered (EEG, 0.5-30 Hz; EMG, 20-200 Hz), then digitized at a sampling rate of 128 Hz and recorded by using SLEEPSIGN (Kissei Comtec, Nagano, Japan) as described in refs. 29 and 33. The total amounts of wakefulness and NREM and REM sleep were calculated for 7 h after beginning ONO-4127Na infusion and for 5 h after SeCl 4 administration. The amounts of the various sleep-wake states were expressed in minutes.
Vigilance State Analysis. Polygraphic recordings were automatically scored offline by 10-s epochs as wakefulness or NREM or REM sleep by SLEEPSIGN according to standard criteria (29) . As a final step, defined sleep-wake stages were examined visually, and corrected, if necessary.
Statistical Analysis. All data were expressed as the mean Ϯ SEM (n ϭ 6 or 7). For time course data, amounts of the different sleep-wake states were analyzed by the paired t test, with each animal serving as its own control. For PGD 2 , PGE 2 , and PGF 2␣ contents in the brain of WT mice and the total amounts of each vigilance stage for 5 h or 7 h after drug treatment, one-or two-way ANOVA followed by the Fisher probable least-squares difference (PLSD) test was used to determine whether the difference among groups and genotypes was statistically significant. In all cases, P Ͻ 0.05 was taken as the level of significance.
